Contact: All partnering inquiries should be directed to Corporate Development.

Current collaborationsa

Sumitomo Dainippon Pharma Co. Ltd.

Intercept entered into a license agreement with Sumitomo Dainippon Pharma Co. Ltd. Sumitomo Dainippon has an exclusive license to research, develop, and commercialize obeticholic acid (OCA) as a therapeutic for the treatment of primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) in China (excluding Taiwan). We granted Sumitomo Dainippon an option under the agreement to obtain an exclusive license to commercialize OCA for indications other than PBC and NASH on the same terms as are set forth in the agreement.

aNote: please review our documents filed with the SEC for a complete and comprehensive disclosure of our strategic collaborations and research arrangements.